Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia

Abstract

Aim Exosomes, the nano-units (<200nm), released from diverse cell types in the extracellular body fluid, possess non-immunogenic property and ability to cross blood-brain barrier (BBB). Since exosomes carry biological information from their cells of origin, we hypothesize that priming cells with potential therapeutic agents release improved cellular contents through exosomes. Curcumin possesses anti-oxidative, anti-inflammatory properties and provides a promising treatment for cerebral diseases and therefore, the aim of the study is to establish that mouse brain endothelial cells (MBEC) when primed with curcumin (7.5μM), release alleviated exosome population that can help recover endothelial cell (EC) layer permeability. Methodology Homocysteine is a well-known causative factor of BBB disruption; therefore, homocysteine-treated ECs were used as a model of BBB disruption and curcumin-primed exosomes were utilized to check their potential for mitigating EC disruption. MBEC were treated with curcumin and exosome were isolated by using ultracentrifugation and immunoprecipitation. Expression levels of junction proteins were detected by Western blot and Immunocytochemistry assays. Endothelial cell permeability was analyzed with FITC BSA leakage assay using transwell permeable supports. Key Findings Exosomes derived from curcumin-treated (primed) cells (CUR-EXO) alleviated oxidative stress, tight junctions (ZO-1, claudin-5, occludin), adherent junction (VE-cadherin) proteins and EC layer permeability induced during EC damage due to high homocysteine levels (hyperhomocysteinemia). Significance In conclusion, the study potentiates the use of CUR-EXO for cerebral diseases where drug delivery is still a challenge. The results also pave the way to novel translational therapies for cerebral diseases by maintaining and establishing therapeutic conservatories via primed exosomes.

Modularized Extracellular Vesicles: The Dawn of Prospective Personalized and Precision Medicine

“…Small lipophilic molecules, such as antioxidants, curcumin, and anticancer agents, can be passively loaded into EVs or EVMs by simple incubation 52, 93, 94. Drugs, including curcumin, show advanced stability and bioavailability when encapsulated compared to free‐state drugs and have been successfully used in preclinical research 95.…”

Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells

“…urine, saliva, cerebrospinal fluid) and in conditioned cell culture media (12). They are formed in multivesicular bodies (MVB) inside the cells (5, 12). Exosomes naturally function as intercellular messengers, carrying RNA and proteins (13).…”

“…Exosomes naturally function as intercellular messengers, carrying RNA and proteins (13). Recently, exosomes have begun to be explored for use as drug delivery vehicles for nucleic acids (14-19), gene delivery (20), and small molecule drugs, such as curcumin (12, 21, 22), and doxorubicin (23). It was demonstrated that exosomes have the exceptional ability to interact with cellular membranes, and deliver their payload to target cells (24, 25).…”

Therapeutic Potential of Natural Product-Based Oral Nanomedicines for Stroke Prevention

“…15 Exosomes (<200 nm) released from diverse cell types in the extracellular fluid are nonimmunogenic and possess the ability to cross the BBB. 45 Since exosomes carry biological information from their cells of origin, encapsulating or priming cells with potential therapeutic agents has been shown to improve cellular delivery through exosomes. Xin et al 46 suggested that intravenous administration of exosomes derived from mesenchymal stromal cells to a rat stroke model might improve functional recovery and enhance neurite remodeling, neurogenesis, and angiogenesis.…”